chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I was to fly out around Dec 7th for holiday but my COVID-19 test came back positive not 5 days after booster. 1/19/2022 I found out results to a routine blood test that I had some unusual retention in iron. Was referred to a Hematologist and did a 2nd blood test where it found a single gene for Hemochromatosis but was at only a low risk for it because of this. Also, he said it could be my alcohol intake that could be causing it and I have been reducing intake by 50% and will be doing another blood test on 29th.
Very dense, widespread, papular/erythematous rash in clusters on trunk and proximal extremities.
This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INDURATION (arm is quite hard near injection site), VACCINATION SITE SWELLING (arm is swollen near injection site) and VACCINATION SITE ERYTHEMA (arm is red near injection site) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported.On 19-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form.On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE INDURATION (arm is quite hard near injection site), VACCINATION SITE SWELLING (arm is swollen near injection site) and VACCINATION SITE ERYTHEMA (arm is red near injection site). At the time of the report, VACCINATION SITE INDURATION (arm is quite hard near injection site), VACCINATION SITE SWELLING (arm is swollen near injection site) and VACCINATION SITE ERYTHEMA (arm is red near injection site) outcome was unknown. Concomitant medication information was not provided by the reporter.Treatment information was not provided by the reporter.
3 hrs post vax pt noted to look pale & found to be limp when picked up; ? if eyes rolled back; -perioral cyanosis; responded to shaking stimulation; In ER t100.6 102 on recheck; also ? of twitch of face 1/2 hr p/event;
Severe and lasting body and muscle aches, headaches, fatigue, loss of consciousness, pain, muscle soreness and tightness, joint pain, and overall decline in health and mental and physical health and fitness
Fever > 103, fatigue, headache  - within 4 hrs of receiving vaccine symptoms persisted for 2 days. Pt appeared very ill but was always responsive. Without s/s rhinorrhea/cough/rash.
pt devel t103 & shakes; APAP given for temp temp keeps coming bac to 103; s/s w/in 36 hr p/immun given pt will be seeing MD for eval;
SMALL AMOUNT OF BLOOD FROM VAGINA; DISCHARGE FROM VAGINA; This spontaneous report received from a patient via social media via a company representative concerned a 61 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on AUG-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On 08-FEB-2022, the patient experienced discharge from vagina. On an unspecified date, the patient experienced small amount of blood from vagina. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from small amount of blood from vagina, and the outcome of discharge from vagina was not reported. This report was non-serious.
After completion of administering vaccine, patient fainted while sitting in a chair. Recorder was able to assist patient so he did not fall out of the chair. Patient was unresponsive for approx 10-12 seconds. Patient sat up, looked around and was able to converse with Mom and recorder. Alert, awake and oriented x 4. Patient was able to walk unassisted out of clinic building.
shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient (pt) of unknown age. No information was provided regarding concomitant medications, concurrent conditions or medical history. On or about 13-NOV-2014, the pt was inoculated with the zoster vaccine live (ZOSTAVAX) vaccine at a health department as recommended for routine adult health maintenance and for the prevention of shingles (dose, route, and lot # not provided). Subsequently, pt. vaccination the pt, was treated by physician for shingles,( date unspecified date). As a direct and proximate result of zoster vaccine live (ZOSTAVAX)vaccine, and/or despite receiving zoster vaccine live (ZOSTAVAX) for long-term prevention of shingles, the pt suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the pt had suffered and would continue to suffer significant medical expenses, including but not limited to costs for hospitalization (unknown date), physician care, monitoring, treatment, medications and supplies and suffered ongoing injuries, pain and other damages. The outcome of the event was considered not recovered.
This spontaneous report was received from a medical assistant and refers to a 4 month old patient of unknown gender. No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided. On 30-MAR-2016, the patient was vaccinated with an improperly stored dose of ROTATEQ, orally, lot # L013202, expiration date: 27-JAN-2017, (dose was not reported). According to the reporter, the vaccines were stored at a temperature of 50.2 degrees Fahrenheit for 9 hours and the temperature excursion took place due to unit adjustment with the door open for stock counting. There was no previous temperature excursion reported. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Chest pain, fatigue, tachycardia, palpitations, pain in the arm.
pt recv vax & exp chills, tiredness & was not feeling well the evening p/vax;on the 2nd day exp diarrhea which was stated as cont @ the time of reporting 2 days p/vax;reporter states feels flu shot somehow aggravated already present illnessAnnual follow-up received 10/02/00 provided no additional data.
REDNESS, RASH, SLIGHT SWELLING, WARMNESS TO THE TOUCH, SLIGHT ITCHY, DRY/SCALY SKIN.
Information has been received from a registered nurse who reported an ocular exposure with GARDASIL vaccine (lot# not reported) on 05-JUN-2008 caused by a syringe malfunction while administering the vaccine to the patient. This was not a GARDASIL vaccine pre-filled syringe. The nurse is not experiencing any problems with her eyes. Patient outcome was not reported. Additional information has been requested.
he is ill; Unable to breathe; stomach pain which is awful; double vision; sweaty; achy; swelling and hardness and redness at injection site; red face; sore throat; skin was white; dizziness; weakness; fever; nausea; chills; joint pain; muscle pain; fatigue; swelling and hardness and redness at injection site; swelling and hardness and redness at injection site; headache; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of DYSPNOEA (Unable to breathe), ILLNESS (he is ill), ABDOMINAL PAIN UPPER (stomach pain which is awful), DIPLOPIA (double vision) and HYPERHIDROSIS (sweaty) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039A21A and 010A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Vomiting since January 2021.   On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 27-Mar-2021, the patient experienced ABDOMINAL PAIN UPPER (stomach pain which is awful), DIPLOPIA (double vision), HYPERHIDROSIS (sweaty), PAIN (achy), VACCINATION SITE INDURATION (swelling and hardness and redness at injection site), ERYTHEMA (red face), OROPHARYNGEAL PAIN (sore throat), PALLOR (skin was white), DIZZINESS (dizziness), ASTHENIA (weakness), PYREXIA (fever), NAUSEA (nausea), CHILLS (chills), ARTHRALGIA (joint pain), MYALGIA (muscle pain), FATIGUE (fatigue), VACCINATION SITE ERYTHEMA (swelling and hardness and redness at injection site), VACCINATION SITE SWELLING (swelling and hardness and redness at injection site) and HEADACHE (headache). On 28-Mar-2021, the patient experienced DYSPNOEA (Unable to breathe). On 01-Apr-2021, the patient experienced ILLNESS (he is ill). At the time of the report, DYSPNOEA (Unable to breathe), ILLNESS (he is ill), ABDOMINAL PAIN UPPER (stomach pain which is awful), DIPLOPIA (double vision), HYPERHIDROSIS (sweaty), PAIN (achy), VACCINATION SITE INDURATION (swelling and hardness and redness at injection site), ERYTHEMA (red face), OROPHARYNGEAL PAIN (sore throat), PALLOR (skin was white), DIZZINESS (dizziness), ASTHENIA (weakness), PYREXIA (fever), NAUSEA (nausea), CHILLS (chills), ARTHRALGIA (joint pain), MYALGIA (muscle pain), FATIGUE (fatigue), VACCINATION SITE ERYTHEMA (swelling and hardness and redness at injection site), VACCINATION SITE SWELLING (swelling and hardness and redness at injection site) and HEADACHE (headache) outcome was unknown.            No relevant concomitant medications were reported.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 28-Apr-2021: NNI; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start dates of the events, a causal relationship cannot be excluded.
Pt had headaches, dizziness, and fever. Vaccine given on 4/28/12 symptoms began same day at 6:00 pm. Pt was given MCV4 twice same day!
COVID SHOT MURDERED THREE PEOPLE I KNOW; This spontaneous report received from a consumer via a company representative via social media concerned 3 patients of unspecified age, sex, race and ethnic origin.  No past medical history or concurrent conditions were reported. The patient received Covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: unknown and expiry: unknown) dose, start therapy date were not reported, 1 total administered for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot number. No concomitant medications were reported.  On an unspecified date, the reporter stated that, the J&J (Johnson and Johnson) covid shot murdered three people I know. On an unspecified date, the patient died from unknown cause of death. It was unknown if autopsy was performed. The action taken with Covid-19 vaccine ad26.cov2.s was not applicable. This report was serious (Death).; Sender's Comments: V0: 20211230706-COVID-19 VACCINE AD26.COV2.S- covid shot murdered three people I know. This event(s) is considered unassessable. The event(s) has unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).; Reported Cause(s) of Death: UNKNOWN CAUSE OF DEATH
Information has been received from a 22 year old female medical student who in 1988 was vaccinated with a first dose of MUMPSVAX (lot number not provided) and on an unspecified date was vaccinated with a second dose of MUMPSVAX (lot number not provided). Concomitant therapy included separate vaccinations with MMR vaccine. Subsequently the patient has lost her immunity (negative MUMPS TITER). The patient's outcome was not reported. Additional information has been requested.
C/o onset severe pain onset at 8 PM 9/16/03. States lifted heavy object after receiving immunization. C/o pain at injection site, down arm to wrist.
Swelling in underarms (at where armpit meets chest), more significant in left armpit (side of vaccine) but present on both sides. Noticed as soon as arrived home from clinic. Currently persistent still 9 days later. Not worsening but not improving. Some discomfort from this swelling. No swelling or redness of actual injection site at any point. Also had headache, arm and body aches and pains of muscle/bone, and fatigue but these resolved within a few days. Only swelling in armpits persists.
same day redness, swelling @ inj site, redness progressed to wrist;very painful;pt weak, lethargic;very irritable & feverish;seen @ urgent care;dx allerg rxn;
Prediabetes; GERD; GERD; This is a spontaneous report received from contactable reporter(s) (Other HCP).  A 69-year-old female patient received BNT162b2 (BNT162B2), on 02Apr2021 as dose 2, single (Batch/Lot number: unknown) at the age of 68 years intramuscular for covid-19 immunisation. The patient's relevant medical history included: "GAD" (unspecified if ongoing); "Breast cancer", start date: 2012 (unspecified if ongoing), notes: Pertinent Details: Bilateral mastectomy; "Bilateral mastectomy" (unspecified if ongoing); "Anxiety" (ongoing); "Dep" (ongoing); "GERD" (ongoing). Concomitant medication(s) included: LEXAPRO oral taken for anxiety, depression (ongoing); PROTONIX [PANTOPRAZOLE SODIUM SESQUIHYDRATE] oral taken for gastrooesophageal reflux disease (ongoing). Vaccination history included: BNT162b2 (Dose: 1st; Route of administration: Intramuscular; Batch/Lot number: Not Available / Provided at Time of Report Completion), administration date: 12Mar2021, when the patient was 68-year-old, for COVID-19 immunization. The following information was reported: GASTROOESOPHAGEAL REFLUX DISEASE (non-serious), DISEASE RECURRENCE (non-serious) all with onset 01Aug2022, outcome "unknown" and all described as "GERD"; GLUCOSE TOLERANCE IMPAIRED (non-serious) with onset 01Aug2022, outcome "unknown", described as "Prediabetes". Therapeutic measures were taken as a result of gastrooesophageal reflux disease, disease recurrence.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sudden severe  food allergies, Eye anurism, muscle weakness, joint swelling and pain,headaches
Patient developed sudden hearing loss.  Was evaluated by ENT and was found to have moderate sensorineural hearing loss for the right ear and severe to profound hearing loss for the left ear.  This was new.  He did not significantly improve with a course of prednisone.
A few minutes after administration of Varivax and Havrix, pt had a case of vasovagel syncope. Pt was standing and fell forward, striking his head upon the ground. Pt has an LoC lasting approximately 15 seconds.  Pt regained consciousness and was instructed to stay laying down. Pt was evaluated by the clinic medical director, and was sat up approximately 5 minutes after the initial event. 30 seconds after sitting up pt began to shake and had a second LoC that lasted approximately 5 seconds. Full recovery time took approximately 45 minutes.
Havrix given on 2/1/2022 had expired on 1/28/2022
Cold; Fall; Stiffness; Sprained ankle; Scratch; Pain; This spontaneous case was reported by a consumer and describes the occurrence of NASOPHARYNGITIS (Cold), FALL (Fall), MUSCULOSKELETAL STIFFNESS (Stiffness), LIGAMENT SPRAIN (Sprained ankle) and SCRATCH (Scratch) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. On an unknown date, the patient experienced NASOPHARYNGITIS (Cold), FALL (Fall), MUSCULOSKELETAL STIFFNESS (Stiffness), LIGAMENT SPRAIN (Sprained ankle), SCRATCH (Scratch) and PAIN (Pain). At the time of the report, NASOPHARYNGITIS (Cold), FALL (Fall), LIGAMENT SPRAIN (Sprained ankle) and SCRATCH (Scratch) outcome was unknown and MUSCULOSKELETAL STIFFNESS (Stiffness) and PAIN (Pain) was resolving. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  No treatment medication information provided  No concomitant medication information provided
Pt recv vax in 1997; post vax lab data revealed pt to be "borderline protected"
Sore arm 4pm (2/8/2021) -12pm (2/9/2021) Muscle Aches 9pm (2/8/2021) -9am (2/9/2021) Chills and Fever 1030pm (2/8/2021) - 9am (2/9/2021) Headache 1am-9am (2/9/2021) Nausea 1030pm (2/8/2021) -9am (2/9/2021)
I contracted COVID-19 on 02/25/2023. I had congestion, dry cough and scratchy throat. I then seen my provider with curbside and he prescribed medications TESSALON PERLES and MEDROL. I completed my doses of medications. I retested for COVID-19 on 03/07/2023 and 03/09/2023 both negative.
Pt recvd 2nd dose of the series of Hep B vax on 18JUN92 @ 9PM; @ approx 9PM on 18JUN92 pt devel sx of diarrhea & puffiness of eyes; eyes puffy approx 11 hrs; also skin rash;
Covered in itchy rash and hives.  It started as rash and hives on chest and abdomen then spread to back, arms, legs neck and eyelids.
Approximately 2 days after vaccination, Pt developed a blister at the injection  site along with right leg pain and body numbness. These symptoms  lasted 2 days and have resolved
0 - No symptoms on day of injection.  Perhaps brief chills overnight but no fever detected.  1 - Next morning reported itching, and we found rashes on both forearms.  One of the rashes was on and behind his left ear, and the left ear was swollen.  Took 1 Zyrtec at bedtime.  2 - Following morning, swelling of ear had not declined, plus there was  now swelling of bottom lip and right eyelid.  No problem eating, speaking, or swallowing.  About 48hrs after injection, all swelling was gone, previously swollen areas appear bruised.  Rashes and itching continue, temporarily relieved by Benadryl oral and/or cream.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Physician). The reporter is the patient.  A 37-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 09May2021 as dose 1, single (Batch/Lot number: unknown) and on 04Jun2021 as dose 2, single (Batch/Lot number: unknown) at the age of 36 years for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 04Dec2021 as dose 3 (booster), single (Batch/Lot number: unknown) and on 29Jun2022 at 16:00 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine nrvv ad (chadox1 ncov-19) (COVID-19 VACCINE ASTRAZENECA), on 01Dec2021 as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Vur/atrophied kidney" (unspecified if ongoing); "Bicuspid av" (unspecified if ongoing); "Anxiety" (unspecified if ongoing); "B12 def" (unspecified if ongoing); "Low bone mass" (unspecified if ongoing). Concomitant medication(s) included: CRESTOR, start date: 10Sep2020, stop date: 04Jul2022; LAMICTAL, start date: 01Dec2021; B12-VITAMIIN, start date: 01May2021; TRINTELLIX, start date: 08Oct2020; JUNEL, start date: 06Apr2019. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results, notes: COVID 19 Treatment; Negative, notes: I had one borderline negative test; Positive, notes: Then it was positive Again. Therapeutic measures were taken as a result of vaccination failure, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This spontaneous report as received from a physician refers to a 10 week old patient. On 21-AUG-2017, the patient was vaccinated with PEDVAXHIB (dose, route of administration, lot # and expiration date were not reported) for prophylaxis. On 21-AUG-2017, the patient experienced incorrect product storage.
Aggravated my Neuropothy for approximately 3 weeks.  Also affected muscles in Right Foot.  Every night Right Foot would get "BURNING HOT" & would have to soak foot in cold water.  For last 10 days of problems, Right Foot, Middle of Leg, and Total Knee  TOTALLY SWELLED UP AND STAYED THAT WAY FOR THAT LAST 10 DAYS! Burning foot is no longer and  swelling is almost gone.
Started feeling achy; temperature of 99.2; Sore arm; This is spontaneous report from a contactable consumer (patient). A 64-year-old female patient received the first dose bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 08Jan2021 at single dose for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced sore arm on 08Jan2021, temperature of 99.2 and started feeling achy on 09Jan2021. Event details: The patient received the first dose of the vaccine yesterday (08Jan2021). Yesterday night, she started with a sore arm which she expected then this afternoon (09Jan2021) she started to experience feeling achy and when she checked her temperature it was 99.2, for the sore arm last night and this morning she took Ibuprofen for treatment. The outcome of the events was unknown.   Information on the batch/lot number has been requested.
severe redness on arm that comes to axillary area; This case was reported by a nurse via call center representative and described the occurrence of erythema of extremities in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st March 2022, the patient received the 1st dose of Shingrix. On an unknown date, several days after receiving Shingrix, the patient experienced erythema of extremities. On an unknown date, the outcome of the erythema of extremities was recovered/resolved.   It was unknown if the reporter considered the erythema of extremities to be related to Shingrix.     Additional Information: GSK Receipt Date: 10-JUN-2022 Reporter's Comments:  The patient received Shingrix and developed a severe redness on her arm. A 750cm that also comes to the axillary area. At the time of the reporting patient was okay with no symptoms. The reporter consented to follow up.
Started with sharp left flank pain and 11/07 - went to urgent care on 11/08 and was diagnosed with acute diverticulitis.